Skip to main content

Monopar宣布其新获专利将扩大对2b/3期临床领先候选药物Validive®的保护

Written by Customer Service on . Posted in Public Companies.

伊利诺伊州维尔梅特, Nov. 10, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc.（Nasdaq: MNMPR，一家临床阶段生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法）今天宣布了其2b/3期临床阶段领先候选药物Validive（可乐定HCl粘膜球菌片）最新获批的一系列专利。这些专利（包括美国专利号10,675,271）提供了涵盖“用于预防和/或治疗化学不良副作用的可乐定和/或可乐定衍生物”的权利要求。
“最近获得授权的这些专利扩大了在癌症患者中使用Validive的专利保护范围，”Monopar首席科学官Andrew Mazar博士表示。“具体来说，在2035年之前，专利将为Validive预防或治疗常见化疗相关副作用（如胃肠道疾病、呼吸系统疾病、疲劳和头痛）的潜在能力提供保护。”关于Monopar Therapeutics Inc.Monopar Therapeutics是一家临床阶段生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法。Monopar处于不同研发阶段的产品包括：用于预防口咽癌症患者因化疗引起严重口腔黏膜炎的Validive®；用于治疗晚期软组织肉瘤的camsirubicin；以及用在晚期癌症和重症新冠肺炎的后期临床前抗体MNPR-101。如需获取更多信息，请访问：www.monopartx.com。前瞻性声明本新闻稿所载关于非历史事实事项的声明属于1995年《私人证券诉讼改革法案》中所述的“前瞻性声明”。“可能”、“将会”、“能够”、“将要”、“应该”、“预料”、“计划”、“预期”、“意在”、“相信”、“估计”、“预示”、“预测”、“潜在”、“继续”、“目标”和类似表达旨在标示前瞻性声明，但并非所有前瞻性声明都包含这些标示词。这些前瞻性声明的例子包括关于以下内容的声明：Monopar按计划在年底前启动Validive 2b/3期临床试验的能力；Validive预防或治疗化疗相关常见副作用（如胃肠道疾病、呼吸系统疾病、疲劳和头痛）的潜力；Validive在接受化疗的患者中预防口腔粘膜炎的潜力；Monopar“开发疗法来提高正在接受治疗的癌症患者的生活质量”这一使命的推进情况；Validive专利将加强并保护Monopar的知识产权组合。前瞻性声明涉及风险和不确定性，包括但不限于Monopar需要筹集更多资金或与合作伙伴合作以完成Validive未来的临床开发和潜在商业化（包括如果Monopar决定将目前计划的开发活动扩展到OPC以外的化疗所带来的其他不良副作用），以及与疗法的研究、开发、监管审批和商业化相关的重大一般风险和不确定性。实际结果可能与此类前瞻性声明中明示或暗示的结果存在重大差异。在Monopar向证券交易委员会提交的文件中，针对各种风险提供了更全面的描述。本新闻稿中包含的所有前瞻性声明仅适用于截至声明发布之日的情形。Monopar没有义务更新此类声明以反映声明作出后发生的事件或存在的情况。本新闻稿中包含的任何前瞻性声明仅代表Monopar截至本文日期的观点，不应被视为代表其后任何日期的意见。联系方式：Monopar Therapeutics Inc.
投资者关系：
Kim R. Tsuchimoto
首席财务官
kimtsu@monopartx.com在社交媒体上关注Monopar以获取最新消息：
Twitter – @MonoparTx   LinkedIn – Monopar Therapeutics  

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.